A comprehensive view of Regeneron Pharmaceuticals Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Regeneron files Taiwanese patent application for medical device packaging for or a sterile syringe and related methods; invention may include a flexible tray having a cavity for containing the syringe: Application No. TW20200125581 20200729

Regeneron and Sanofi’s injectable anti-inflammatory drug Dupixent dupilumab cleared in US to treat children six months to five years old with atopic dermatitis or eczema; drug had previously been approved for children aged six years and older

FDA accepts priority review of Regeneron and Sanofi’s sBLA for Dupixent Medical dupilumab injectable to treat adults with prurigo nodularis; if approved, Dupixent would be only drug to treat prurigo nodularis in US

Regeneron completes acquisition of clinical-stage biopharmaceutical company Checkmate Pharmaceuticals for US$10.50 per share of common stock, or approximately US$250M

Regeneron buys exclusive worldwide rights to Libtayo injectable cancer drug from Sanofi for US$900M; Regeneron’s 2021 sales of Libtayo up 13% from 2020 to US$306M, with Sanofi sales of Libtayo up 91% last year to US$129M

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count